La Nua Day Hospital Mental Health Centre Trials

La Nua Day Hospital Mental Health Centre	Welcome, Profile Billing Logout

Trial + Data / Events

Status

Region

Interventions

Sponsor

Conditions

Primary compl

Study compl

Allen, Rebecca H

NCT05711940: Efficacy, Safety, and Tolerability of Two Administrations of COMP360 in Participants With TRD

Recruiting

568

Europe, Canada, US, RoW

Psilocybin, COMP360

COMPASS Pathways

Treatment Resistant Depression

02/26

12/26

IMPACT-2, NCT06215261: An Evaluation of the Safety and Efficacy of Methylone for the Treatment of PTSD

Recruiting

Europe, US, RoW

Methylone

Transcend Therapeutics

Post Traumatic Stress Disorder

12/25

MeRT-TBI-005, NCT02990793: Clinical Trial to Evaluate the Safety and Efficacy of MeRT Treatment in Post-Traumatic Stress Disorder

Recruiting

N/A

152

Active MeRT Treatment, rTMS Active Stimulator, Sham MeRT Treatment, rTMS Sham Stimulator

Wave Neuroscience, Texas A&M University, GilpinPhillips BIOMED, LLC, Peachtree BioResearch Solutions

PostTraumatic Stress Disorder, Traumatic Brain Injury, Postconcussive Symptoms

08/25

10/25

OLO, NCT05819021: Open Label Optimization Study

Active, not recruiting

N/A

1000

SAINT® Neuromodulation System (NMS), TMS

Magnus Medical

Major Depressive Disorder

10/26

04/27

RECOVER, NCT03887715: A Prospective, Multi-center, Randomized Controlled Blinded Trial Demonstrating the Safety and Effectiveness of VNS Therapy® System as Adjunctive Therapy Versus a No Stimulation Control in Subjects With Treatment-Resistant Depression

Recruiting

N/A

6800

Vagus Nerve Stimulation (VNS), VNS

LivaNova

Treatment Resistant Depression

02/28

12/30

DiBuono, Mark

REGAiN-1B, NCT04873232: A 6-Month Extension Study of VMDN-003-2 to Assess Engensis in Participants With Painful Diabetic Peripheral Neuropathy

Completed

106

Engensis, Placebo

Helixmith Co., Ltd.

Diabetic Peripheral Neuropathy

09/23

07/24

NCT05397639 / 2021-003405-22: Masupirdine for the Treatment of Agitation in Dementia of the Alzheimer's Type

Recruiting

375

Europe, US, RoW

Masupirdine 50 mg, SUVN-502, Masupirdine 100 mg, Placebo

Suven Life Sciences Limited, Suven Life Sciences Ltd

Agitation, Alzheimer's Type Dementia

12/25

NCT05711940: Efficacy, Safety, and Tolerability of Two Administrations of COMP360 in Participants With TRD

Recruiting

568

Europe, Canada, US, RoW

Psilocybin, COMP360

COMPASS Pathways

Treatment Resistant Depression

02/26

12/26

REFOCUS-ALZ, NCT05026177: Simufilam 50 mg or 100 mg for Mild-to-Moderate Alzheimer's Disease

Terminated

1125

Canada, US, RoW

Simufilam, PTI-125, Placebo

Cassava Sciences, Inc., Premier Research Group plc

Alzheimer Disease

12/24

NCT05026866: A Donanemab (LY3002813) Study in Participants With Preclinical Alzheimer's Disease (TRAILBLAZER-ALZ 3)

Recruiting

2996

Japan, US

Donanemab, LY3002813, Placebo

Eli Lilly and Company

Alzheimer Disease

11/27

NCT05439603: ANC-501 in the Treatment of Adults With Major Depressive Disorder

Completed

ANC-501

Ancora Bio, Inc. d/b/a EmbarkNeuro, Inc.

Major Depressive Disorder

08/23

10/23

NCT05081245: ML-004 in Adolescents and Adults With Autism Spectrum Disorders (ASD)

Recruiting

150

Canada, US, RoW

ML-004 (IR)/(ER) tablet, ML-004 Placebo

MapLight Therapeutics

Autism Spectrum Disorder

10/26

11/26

CYPRESS, NCT05895552: A Phase 2 Study of RTA 901 (BIIB143) in Participants With Diabetic Peripheral Neuropathic Pain

Terminated

209

RTA 901, BIIB143, Cemdomespib, RTA 901-Matching Placebo

Biogen

Diabetic Peripheral Neuropathic Pain

11/24

PROGRESS-AD, NCT06079190: Efficacy and Safety of GSK4527226 [AL101] in Participants With Early Alzheimer's Disease

Active, not recruiting

367

Europe, Canada, US, RoW

GSK4527226, Placebo

GlaxoSmithKline, Alector Inc.

Alzheimer's Disease

11/26

NCT03788811: ERG Components in Schizophrenia and Bipolar Disorder Type I

Active, not recruiting

N/A

300

Canada, US, RoW

ERG assessment (RSPA)

diaMentis Inc.

Schizophrenia, Bipolar I Disorder

12/24

Robison, Reid

NCT05624268: Efficacy, Safety, and Tolerability of COMP360 in Participants With TRD

Active, not recruiting

255

Psilocybin, COMP360

COMPASS Pathways

Treatment Resistant Depression

06/25

04/26

EBS-101-TD-391, NCT06021522: A Study to Evaluate Long-term Safety of Ecopipam Tablets in Children, Adolescents and Adults With Tourette's Disorder

Recruiting

150

Europe, Canada, US, RoW

Ecopipam, Ecopipam Hydrochloride

Emalex Biosciences Inc.

Tourette Syndrome

12/26

03/27

D1AMOND, NCT05615220: Ecopipam Tablets to Study Tourette's Disorder in Children, Adolescents and Adults

Completed

216

Europe, Canada, US, RoW

Ecopipam Hydrochloride

Emalex Biosciences Inc.

Tourette Disorder

01/25

02/25

NCT05711940: Efficacy, Safety, and Tolerability of Two Administrations of COMP360 in Participants With TRD

Recruiting

568

Europe, Canada, US, RoW

Psilocybin, COMP360

COMPASS Pathways

Treatment Resistant Depression

02/26

12/26

NCT05081245: ML-004 in Adolescents and Adults With Autism Spectrum Disorders (ASD)

Recruiting

150

Canada, US, RoW

ML-004 (IR)/(ER) tablet, ML-004 Placebo

MapLight Therapeutics

Autism Spectrum Disorder

10/26

11/26

BVR-100-102, NCT06037668: A Randomized, Controlled Study of Two At-Home Self-Guided Virtual Reality Interventions for Adults With Social Anxiety Disorder.

Completed

N/A

BVR-100, BES-100

Sumitomo Pharma America, Inc., BehaVR LLC

Social Anxiety Disorder (SAD)

12/23

01/24

Nery, Fabiano G

NCT05711940: Efficacy, Safety, and Tolerability of Two Administrations of COMP360 in Participants With TRD

Recruiting

568

Europe, Canada, US, RoW

Psilocybin, COMP360

COMPASS Pathways

Treatment Resistant Depression

02/26

12/26

Duchemin, Anne-Marie

NCT05711940: Efficacy, Safety, and Tolerability of Two Administrations of COMP360 in Participants With TRD

Recruiting

568

Europe, Canada, US, RoW

Psilocybin, COMP360

COMPASS Pathways

Treatment Resistant Depression

02/26

12/26

Recruiting

N/A

6800

Vagus Nerve Stimulation (VNS), VNS

LivaNova

Treatment Resistant Depression

02/28

12/30

House, Brindley

NCT05711940: Efficacy, Safety, and Tolerability of Two Administrations of COMP360 in Participants With TRD

Recruiting

568

Europe, Canada, US, RoW

Psilocybin, COMP360

COMPASS Pathways

Treatment Resistant Depression

02/26

12/26

Lindsay, Tenekia

NCT05711940: Efficacy, Safety, and Tolerability of Two Administrations of COMP360 in Participants With TRD

Recruiting

568

Europe, Canada, US, RoW

Psilocybin, COMP360

COMPASS Pathways

Treatment Resistant Depression

02/26

12/26

Kwon, Sarah

NCT05711940: Efficacy, Safety, and Tolerability of Two Administrations of COMP360 in Participants With TRD

Recruiting

568

Europe, Canada, US, RoW

Psilocybin, COMP360

COMPASS Pathways

Treatment Resistant Depression

02/26

12/26

ABT-CIP-10494, NCT06423430: Treatment ResistAnt Depression Subcallosal CingulatE Network DBS (TRANSCEND)

Recruiting

N/A

100

Sham-stimulation, Active-stimulation

Abbott Medical Devices

Treatment Resistant Depression

04/27

04/29

Recruiting

N/A

6800

Vagus Nerve Stimulation (VNS), VNS

LivaNova

Treatment Resistant Depression

02/28

12/30

Pollard, Ronnie

NCT05711940: Efficacy, Safety, and Tolerability of Two Administrations of COMP360 in Participants With TRD

Recruiting

568

Europe, Canada, US, RoW

Psilocybin, COMP360

COMPASS Pathways

Treatment Resistant Depression

02/26

12/26

Matte, Raymond

NCT05711940: Efficacy, Safety, and Tolerability of Two Administrations of COMP360 in Participants With TRD

Recruiting

568

Europe, Canada, US, RoW

Psilocybin, COMP360

COMPASS Pathways

Treatment Resistant Depression

02/26

12/26

Avalos, Moraima

NCT05711940: Efficacy, Safety, and Tolerability of Two Administrations of COMP360 in Participants With TRD

Recruiting

568

Europe, Canada, US, RoW

Psilocybin, COMP360

COMPASS Pathways

Treatment Resistant Depression

02/26

12/26

Trial + Data / Events

Status

Region

Interventions

Sponsor

Conditions

Primary compl

Study compl

Allen, Rebecca H

NCT05711940: Efficacy, Safety, and Tolerability of Two Administrations of COMP360 in Participants With TRD

Recruiting

568

Europe, Canada, US, RoW

Psilocybin, COMP360

COMPASS Pathways

Treatment Resistant Depression

02/26

12/26

IMPACT-2, NCT06215261: An Evaluation of the Safety and Efficacy of Methylone for the Treatment of PTSD

Recruiting

Europe, US, RoW

Methylone

Transcend Therapeutics

Post Traumatic Stress Disorder

12/25

MeRT-TBI-005, NCT02990793: Clinical Trial to Evaluate the Safety and Efficacy of MeRT Treatment in Post-Traumatic Stress Disorder

Recruiting

N/A

152

Active MeRT Treatment, rTMS Active Stimulator, Sham MeRT Treatment, rTMS Sham Stimulator

Wave Neuroscience, Texas A&M University, GilpinPhillips BIOMED, LLC, Peachtree BioResearch Solutions

PostTraumatic Stress Disorder, Traumatic Brain Injury, Postconcussive Symptoms

08/25

10/25

OLO, NCT05819021: Open Label Optimization Study

Active, not recruiting

N/A

1000

SAINT® Neuromodulation System (NMS), TMS

Magnus Medical

Major Depressive Disorder

10/26

04/27

Recruiting

N/A

6800

Vagus Nerve Stimulation (VNS), VNS

LivaNova

Treatment Resistant Depression

02/28

12/30

DiBuono, Mark

REGAiN-1B, NCT04873232: A 6-Month Extension Study of VMDN-003-2 to Assess Engensis in Participants With Painful Diabetic Peripheral Neuropathy

Completed

106

Engensis, Placebo

Helixmith Co., Ltd.

Diabetic Peripheral Neuropathy

09/23

07/24

NCT05397639 / 2021-003405-22: Masupirdine for the Treatment of Agitation in Dementia of the Alzheimer's Type

Recruiting

375

Europe, US, RoW

Masupirdine 50 mg, SUVN-502, Masupirdine 100 mg, Placebo

Suven Life Sciences Limited, Suven Life Sciences Ltd

Agitation, Alzheimer's Type Dementia

12/25

NCT05711940: Efficacy, Safety, and Tolerability of Two Administrations of COMP360 in Participants With TRD

Recruiting

568

Europe, Canada, US, RoW

Psilocybin, COMP360

COMPASS Pathways

Treatment Resistant Depression

02/26

12/26

REFOCUS-ALZ, NCT05026177: Simufilam 50 mg or 100 mg for Mild-to-Moderate Alzheimer's Disease

Terminated

1125

Canada, US, RoW

Simufilam, PTI-125, Placebo

Cassava Sciences, Inc., Premier Research Group plc

Alzheimer Disease

12/24

NCT05026866: A Donanemab (LY3002813) Study in Participants With Preclinical Alzheimer's Disease (TRAILBLAZER-ALZ 3)

Recruiting

2996

Japan, US

Donanemab, LY3002813, Placebo

Eli Lilly and Company

Alzheimer Disease

11/27

NCT05439603: ANC-501 in the Treatment of Adults With Major Depressive Disorder

Completed

ANC-501

Ancora Bio, Inc. d/b/a EmbarkNeuro, Inc.

Major Depressive Disorder

08/23

10/23

NCT05081245: ML-004 in Adolescents and Adults With Autism Spectrum Disorders (ASD)

Recruiting

150

Canada, US, RoW

ML-004 (IR)/(ER) tablet, ML-004 Placebo

MapLight Therapeutics

Autism Spectrum Disorder

10/26

11/26

CYPRESS, NCT05895552: A Phase 2 Study of RTA 901 (BIIB143) in Participants With Diabetic Peripheral Neuropathic Pain

Terminated

209

RTA 901, BIIB143, Cemdomespib, RTA 901-Matching Placebo

Biogen

Diabetic Peripheral Neuropathic Pain

11/24

PROGRESS-AD, NCT06079190: Efficacy and Safety of GSK4527226 [AL101] in Participants With Early Alzheimer's Disease

Active, not recruiting

367

Europe, Canada, US, RoW

GSK4527226, Placebo

GlaxoSmithKline, Alector Inc.

Alzheimer's Disease

11/26

NCT03788811: ERG Components in Schizophrenia and Bipolar Disorder Type I

Active, not recruiting

N/A

300

Canada, US, RoW

ERG assessment (RSPA)

diaMentis Inc.

Schizophrenia, Bipolar I Disorder

12/24

Robison, Reid

NCT05624268: Efficacy, Safety, and Tolerability of COMP360 in Participants With TRD

Active, not recruiting

255

Psilocybin, COMP360

COMPASS Pathways

Treatment Resistant Depression

06/25

04/26

EBS-101-TD-391, NCT06021522: A Study to Evaluate Long-term Safety of Ecopipam Tablets in Children, Adolescents and Adults With Tourette's Disorder

Recruiting

150

Europe, Canada, US, RoW

Ecopipam, Ecopipam Hydrochloride

Emalex Biosciences Inc.

Tourette Syndrome

12/26

03/27

D1AMOND, NCT05615220: Ecopipam Tablets to Study Tourette's Disorder in Children, Adolescents and Adults

Completed

216

Europe, Canada, US, RoW

Ecopipam Hydrochloride

Emalex Biosciences Inc.

Tourette Disorder

01/25

02/25

NCT05711940: Efficacy, Safety, and Tolerability of Two Administrations of COMP360 in Participants With TRD

Recruiting

568

Europe, Canada, US, RoW

Psilocybin, COMP360

COMPASS Pathways

Treatment Resistant Depression

02/26

12/26

NCT05081245: ML-004 in Adolescents and Adults With Autism Spectrum Disorders (ASD)

Recruiting

150

Canada, US, RoW

ML-004 (IR)/(ER) tablet, ML-004 Placebo

MapLight Therapeutics

Autism Spectrum Disorder

10/26

11/26

BVR-100-102, NCT06037668: A Randomized, Controlled Study of Two At-Home Self-Guided Virtual Reality Interventions for Adults With Social Anxiety Disorder.

Completed

N/A

BVR-100, BES-100

Sumitomo Pharma America, Inc., BehaVR LLC

Social Anxiety Disorder (SAD)

12/23

01/24

Nery, Fabiano G

NCT05711940: Efficacy, Safety, and Tolerability of Two Administrations of COMP360 in Participants With TRD

Recruiting

568

Europe, Canada, US, RoW

Psilocybin, COMP360

COMPASS Pathways

Treatment Resistant Depression

02/26

12/26

Duchemin, Anne-Marie

NCT05711940: Efficacy, Safety, and Tolerability of Two Administrations of COMP360 in Participants With TRD

Recruiting

568

Europe, Canada, US, RoW

Psilocybin, COMP360

COMPASS Pathways

Treatment Resistant Depression

02/26

12/26

Recruiting

N/A

6800

Vagus Nerve Stimulation (VNS), VNS

LivaNova

Treatment Resistant Depression

02/28

12/30

House, Brindley

NCT05711940: Efficacy, Safety, and Tolerability of Two Administrations of COMP360 in Participants With TRD

Recruiting

568

Europe, Canada, US, RoW

Psilocybin, COMP360

COMPASS Pathways

Treatment Resistant Depression

02/26

12/26

Lindsay, Tenekia

NCT05711940: Efficacy, Safety, and Tolerability of Two Administrations of COMP360 in Participants With TRD

Recruiting

568

Europe, Canada, US, RoW

Psilocybin, COMP360

COMPASS Pathways

Treatment Resistant Depression

02/26

12/26

Kwon, Sarah

NCT05711940: Efficacy, Safety, and Tolerability of Two Administrations of COMP360 in Participants With TRD

Recruiting

568

Europe, Canada, US, RoW

Psilocybin, COMP360

COMPASS Pathways

Treatment Resistant Depression

02/26

12/26

ABT-CIP-10494, NCT06423430: Treatment ResistAnt Depression Subcallosal CingulatE Network DBS (TRANSCEND)

Recruiting

N/A

100

Sham-stimulation, Active-stimulation

Abbott Medical Devices

Treatment Resistant Depression

04/27

04/29

Recruiting

N/A

6800

Vagus Nerve Stimulation (VNS), VNS

LivaNova

Treatment Resistant Depression

02/28

12/30

Pollard, Ronnie

NCT05711940: Efficacy, Safety, and Tolerability of Two Administrations of COMP360 in Participants With TRD

Recruiting

568

Europe, Canada, US, RoW

Psilocybin, COMP360

COMPASS Pathways

Treatment Resistant Depression

02/26

12/26

Matte, Raymond

NCT05711940: Efficacy, Safety, and Tolerability of Two Administrations of COMP360 in Participants With TRD

Recruiting

568

Europe, Canada, US, RoW

Psilocybin, COMP360

COMPASS Pathways

Treatment Resistant Depression

02/26

12/26

Avalos, Moraima

NCT05711940: Efficacy, Safety, and Tolerability of Two Administrations of COMP360 in Participants With TRD

Recruiting

568

Europe, Canada, US, RoW

Psilocybin, COMP360

COMPASS Pathways

Treatment Resistant Depression

02/26

12/26



	Diseases Companies Products Productz Mechanisms of Action Sites